Patents by Inventor Ken Lipson

Ken Lipson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of modulating tyrosine protein kinase function with indolinone compounds
    Patent number: 7211600
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: May 1, 2007
    Assignee: Sugen Inc.
    Inventors: Ken Lipson, Gerald McMahon
  • Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
    Publication number: 20050288353
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
    Type: Application
    Filed: August 16, 2005
    Publication date: December 29, 2005
    Inventors: Ken Lipson, Gerald McMahon
  • Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
    Publication number: 20040002534
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
    Type: Application
    Filed: June 23, 2003
    Publication date: January 1, 2004
    Applicant: Sugen, Inc.
    Inventors: Ken Lipson, Gerald McMahon
  • Bis-indolylquinone compounds
    Patent number: 6660763
    Abstract: The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: December 9, 2003
    Assignee: Sugen, Inc.
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris, Jr., Ken Lipson
  • Bis-indolyquinone compounds
    Publication number: 20020156116
    Abstract: The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.
    Type: Application
    Filed: May 4, 2000
    Publication date: October 24, 2002
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris, Ken Lipson
  • Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof
    Patent number: 6376529
    Abstract: The present invention relates to a class of indolylquinone compounds that inhibit GRB-2 adaptor protein function, pharmaceutical compositions comprising these compounds, and methods for ameliorating the symptoms of cell proliferative disorders associated with GRB-2 adaptor protein function using these compounds. The present invention further relates to methods for treating insulin-related disorders, such as diabetes, insulin resistance, insulin deficiency and insulin allergy, and for ameliorating the symptoms of insulin-related disorders, using certain indolylquinone compounds and pharmaceutical compositions thereof. The present invention also relates to novel synthetic methods for the preparation of mono- and bis-indolylquinone compounds.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: April 23, 2002
    Inventors: Peng Cho Tang, Gerald McMahon, G. Davis Harris, Jr., Ken Lipson
  • Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
    Publication number: 20020010203
    Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase.
    Type: Application
    Filed: December 22, 2000
    Publication date: January 24, 2002
    Inventors: Ken Lipson, Gerald McMahon